SORELL HOTEL ADOR
Laupenstrasse 15
Berne 3001
Schweiz
We are a collaborative network of Swiss researchers dedicated to preclinical and clinical cancer research in the field of urogenital tumors. Our network includes a scientific committee comprised of SAKK members and the Swiss cancer researchers, bringing together experts in the field. Attendees can look forward to an engaging event focussing on advances in urogenital cancer research.
Scientific Comittee
Keynote Speakers
Credits
One of our key objectives is to inspire and foster scientific interactions among the various basic, translational, and clinical research groups in the field of urogenital cancers in Switzerland. To facilitate this, we organize an annual networking meeting where researchers present their ongoing work and engage with partners to further develop their ideas or implement project goals.
By translating scientific knowledge into practical solutions, research improves patient outcomes and treatment strategies. The two awards from Astellas & AstraZeneca and Novartis support projects in this field of research.
Applicants can present their project to an interested audience of experts. They have the chance to win one of the two awards:
Event Language: English
CHF 160 without hotel room. Hotel rooms must be booked by the participants.
Detailed information you will find in the agenda (see Download).
This year, we will present two awards. Please send your application to events@sakk.ch by September 30, 2024.
In case of any questions relating to the presentations, please contact Jean-Philippe Theurillat jean-philippe.theurillat@ior.usi.ch. For presenters of projects, participation at the event is free of charge (hotel and registration).
SAKK / ASTELLAS & ASTRAZENECA GU-ONCOLOGY RESEARCH AWARD
The Swiss Group for Clinical Cancer Research (SAKK) and Astellas & AstraZeneca are pleased to announce an award for 10 000 CHF aimed at supporting ongoing translational GU oncology research. The award is sponsored 50% by AstraZeneca and Astellas each.
SAKK / NOVARTIS TRANSLATIONAL PROSTATE CANCER RESEARCH AWARD
The Swiss Group for Clinical Cancer Research (SAKK) and Novartis Pharma Schweiz AG are pleased to announce an award for 20 000 CHF aimed at supporting ongoing translational prostate cancer research.
Further information about the awards.
Main: Astellas Platin: Novartis
Gold: Astra Zeneca, Astra Zeneca/MSD, Bristol Myers Squibb, Janssen